Rosar, F.; Krause, J.; Bartholomä, M.; Maus, S.; Stemler, T.; Hierlmeier, I.; Linxweiler, J.; Ezziddin, S.; Khreish, F.
Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis. Pharmaceutics 2021, 13, 722.
https://doi.org/10.3390/pharmaceutics13050722
AMA Style
Rosar F, Krause J, Bartholomä M, Maus S, Stemler T, Hierlmeier I, Linxweiler J, Ezziddin S, Khreish F.
Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis. Pharmaceutics. 2021; 13(5):722.
https://doi.org/10.3390/pharmaceutics13050722
Chicago/Turabian Style
Rosar, Florian, Jonas Krause, Mark Bartholomä, Stephan Maus, Tobias Stemler, Ina Hierlmeier, Johannes Linxweiler, Samer Ezziddin, and Fadi Khreish.
2021. "Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis" Pharmaceutics 13, no. 5: 722.
https://doi.org/10.3390/pharmaceutics13050722
APA Style
Rosar, F., Krause, J., Bartholomä, M., Maus, S., Stemler, T., Hierlmeier, I., Linxweiler, J., Ezziddin, S., & Khreish, F.
(2021). Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis. Pharmaceutics, 13(5), 722.
https://doi.org/10.3390/pharmaceutics13050722
